Tyra Biosciences (TYRA) Expected to Announce Earnings on Thursday

Tyra Biosciences (NASDAQ:TYRA) is expected to be posting its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect Tyra Biosciences to post earnings of ($0.60) per share for the quarter. Investors may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, May 20, 2026 at 4:00 PM ET.

Tyra Biosciences (NASDAQ:TYRA) last announced its earnings results on Monday, March 2nd. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.03). On average, analysts expect Tyra Biosciences to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Tyra Biosciences Stock Performance

Shares of NASDAQ TYRA opened at $34.01 on Tuesday. Tyra Biosciences has a 1 year low of $8.75 and a 1 year high of $40.65. The firm has a market cap of $2.02 billion, a P/E ratio of -16.92 and a beta of 0.79. The stock has a fifty day moving average price of $35.96 and a two-hundred day moving average price of $28.47.

Insider Activity at Tyra Biosciences

In related news, Director Gilla Kaplan sold 14,295 shares of Tyra Biosciences stock in a transaction on Wednesday, March 25th. The stock was sold at an average price of $36.97, for a total transaction of $528,486.15. Following the completion of the sale, the director owned 28,231 shares of the company’s stock, valued at approximately $1,043,700.07. This trade represents a 33.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 12.50% of the company’s stock.

Hedge Funds Weigh In On Tyra Biosciences

A number of institutional investors have recently modified their holdings of TYRA. Commodore Capital LP raised its holdings in Tyra Biosciences by 226.3% in the 2nd quarter. Commodore Capital LP now owns 3,100,000 shares of the company’s stock worth $29,667,000 after acquiring an additional 2,150,000 shares during the period. Farallon Capital Management LLC boosted its holdings in Tyra Biosciences by 80.7% during the fourth quarter. Farallon Capital Management LLC now owns 2,066,818 shares of the company’s stock valued at $54,337,000 after acquiring an additional 923,000 shares during the period. Caligan Partners LP grew its position in shares of Tyra Biosciences by 266.8% in the third quarter. Caligan Partners LP now owns 696,825 shares of the company’s stock valued at $9,749,000 after purchasing an additional 506,875 shares during the last quarter. Balyasny Asset Management L.P. grew its position in shares of Tyra Biosciences by 139.8% in the second quarter. Balyasny Asset Management L.P. now owns 583,386 shares of the company’s stock valued at $5,583,000 after purchasing an additional 340,142 shares during the last quarter. Finally, State Street Corp increased its stake in shares of Tyra Biosciences by 74.9% in the fourth quarter. State Street Corp now owns 749,463 shares of the company’s stock worth $19,703,000 after purchasing an additional 320,991 shares during the period. Institutional investors own 84.14% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. William Blair assumed coverage on Tyra Biosciences in a report on Tuesday, February 10th. They issued an “outperform” rating for the company. Jefferies Financial Group boosted their price target on shares of Tyra Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a research report on Tuesday, February 3rd. Cantor Fitzgerald began coverage on shares of Tyra Biosciences in a report on Tuesday, February 24th. They issued an “overweight” rating for the company. HC Wainwright raised their price objective on shares of Tyra Biosciences from $30.00 to $45.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. Finally, Wall Street Zen cut shares of Tyra Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, January 24th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $46.50.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.